MRI-guided transurethral ultrasound ablation (TULSA) targeted therapy of urinary retention due to benign prostatic obstruction (BPO) and concordant prostate cancer

D. Samun; A. Lumiani; R. Sroka; R. Muschter

doi:10.1117/12.2614076

2 March 2022 MRI-guided transurethral ultrasound ablation (TULSA) targeted therapy of urinary retention due to benign prostatic obstruction (BPO) and concordant prostate cancer

D. Samun, A. Lumiani, R. Sroka, R. Muschter

Author Affiliations +

Proceedings Volume 11958, Optical Interactions with Tissue and Cells XXXIII; and Advanced Photonics in Urology; 119580F (2022) https://doi.org/10.1117/12.2614076
Event: SPIE BiOS, 2022, San Francisco, California, United States

Abstract

Introduction & Objectives: The objectives of this study were to evaluate the safety and efficacy of targeted customized (transitional zone plus focal/partial to wholegland peripheral zone) TULSA as a treatment for patients in urinary retention due to BPO and concordant prostate cancer (PCa). Materials & Methods: The study included men in chronic urinary retention due to BPO and diagnosed with MRI-guided biopsy-confirmed PCa. All men had either transurethral (n=13) or suprapubic (n=4) catheters or intermittant selfcatheterization (n=3). Patients underwent TULSA as primary treatment, with Gleason Grade Groups from 1-5. Treatment planning and targeted ablation volume was dependent on individual PCa characteristics, and included the total transitional zone. Treatment was performed under permanent MRI control and temperature mapping. Suprapubic catheters for intermittent drainage were administered in all patients and left in place until sufficient voiding was achieved. Adverse events and surgical complications were reported using the Clavien-Dindo classification. Functional outcomes were reported using IPSS (International Prostate Symptom Score). Short-term oncological control was evaluated using multi-parametric MRI (mpMRI) and prostate specific antigen (PSA). Results: Twenty consecutive patients with a follow-up of 12 months were included. The baseline median age was 76 years (66-87). All patients recovered from urinary retention after a median post-treatment catheterization time of 46 days. 12-months oncological control was achieved in 17 of 20 patients. During follow-up, grade IIIa adverse events were observed in n=5 patients (epidydymitis n=5), with no bowelrelated complications. Conclusions: Targeted TULSA appears to offer a good option for men in chronic urinary retention due to BPO with concordant prostate cancer.

Citation Download Citation

D. Samun, A. Lumiani, R. Sroka, and R. Muschter "MRI-guided transurethral ultrasound ablation (TULSA) targeted therapy of urinary retention due to benign prostatic obstruction (BPO) and concordant prostate cancer", Proc. SPIE 11958, Optical Interactions with Tissue and Cells XXXIII; and Advanced Photonics in Urology, 119580F (2 March 2022); https://doi.org/10.1117/12.2614076

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members: $17.00

Non-members: $21.00 ADD TO CART

PROCEEDINGS
8 PAGES

DOWNLOAD PAPER SAVE TO MY LIBRARY

GET CITATION

RIGHTS & PERMISSIONS

Get copyright permission Get copyright permission on Copyright Marketplace

KEYWORDS

Prostate cancer

Ultrasonography

Magnetic resonance imaging

Prostate

Principal component analysis

Safety

Biopsy

Show All Keywords

Keywords/Phrases

Search In:

Publication Years